This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 969764 results found since Jan 2013.

P008 A prospective study on the prognosis of multiple sclerosis in Tunisia: Do we really have a distinct disease course in North Africa?
Conclusion This is the first multicentric study in our country. The present study showed a similar course of MS in a North African population compared to European cohorts. Similar long term prognosis factors were found.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

P016 Evaluation of SNP rs763361 on Gly307Ser gene in multiple sclerosis patients compared to healthy subjects
Conclusion This Case-Control study provided evidence that rs763361 SNP is not correlated to RRMS susceptibility in studied population.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

P021 Role of histamine and diamine oxidase enzyme in Multiple Sclerosis
Conclusions It should be considered that although defect of DAO enzyme can cause elevated serum levels of histamine in MS patients, low level of this enzyme can also elevate serum levels of histamine which can contribute in pathogenesis of MS.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

P024 Effects of recurrent fasting on fatigue and quality of life in patients with multiple sclerosis
Conclusion Our results have shown that fasting during Ramadan can improve the quality of life in MS patients. Furthermore, no unfavorable effect was observed between fatigue before and after fasting. However, larger prospective clinical studies are needed to shed more light on our results.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

P026 Real world use of fingolimod in patients with relapsing remitting multiple sclerosis: A retrospective study utilising the national multiple sclerosis registry in Kuwait
Conclusion Fingolimod treatment was associated with reduced relapse and MRI activity, and improved EDSS score. Discontinuation/withdrawal rates and adverse events were low. Fingolimod presents a promising treatment for MS in Kuwait.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

P027 Severe reactivation of multiple sclerosis after discontinuation of fingolimod: An IRIS-associated phenomenon
Conclusion Our case highlighted the diagnostic dilemma in JC virus seropositive patients who developed relapses after discontinuing potent immunomodulators. Patients who discontinued fingolimod might be at risk of developing IRIS resulting in disease reactivation in the washout period.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st century Steering group
Publication date: Available online 2 March 2015 Source:Multiple Sclerosis and Related Disorders Author(s): Peter Rieckmann , Alexey Boyko , Diego Centonze , Irina Elovaara , Gavin Giovannoni , Eva Havrdová , Otto Hommes , Jurg Kesselring , Gisela Kobelt , Dawn Langdon , Jacques LeLorier , Sarah A Morrow , Celia Oreja-Guevara , Sven Schippling , Christoph Thalheim , Heidi Thompson , Patrick Vermersch While advances in medicine, technology and healthcare services offer promises of longevity and improved quality of life (QoL), there is also increasing reliance on a patient's skills and motivation to optimize all the benefi...
Source: Multiple Sclerosis and Related Disorders - March 6, 2015 Category: Neurology Source Type: research

Impact of multiple sclerosis relapse: The NARCOMS participant perspective
Publication date: Available online 27 March 2015 Source:Multiple Sclerosis and Related Disorders Author(s): Molly Nickerson , Stacey S. Cofield , Tuula Tyry , Amber R. Salter , Gary R. Cutter , Ruth Ann Marrie Acute relapses continue to be a significant aspect of multiple sclerosis (MS) on both the epidemiologic level and the individual patient level. Past work demonstrates residual disability from relapses as well as high patient-reported rates of ineffective relapse treatment. To better characterize the impact of MS relapses on the patient, a relapse-specific survey was administered through the North American Research ...
Source: Multiple Sclerosis and Related Disorders - March 27, 2015 Category: Neurology Source Type: research

Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003)
CONCLUSIONS: DAC HYP demonstrated superior efficacy compared with IFNβ-1a across key clinical, radiographic, and patient-reported MS outcome measures in relapsing MS patients. Risks were manageable with appropriate monitoring. Study Supported by: Biogen Idec and AbbVie Biotherapeutics.Disclosure: Dr. Kappos has received personal compensation for activities with Actelion Pharmaceuticals. Dr. Selmaj has received personal compensation for activities with Genzyme Corporation, Novartis, Ono Pharmaceutical, Roche Diagnostics Corporation, Synthon, Teva Neuroscience, and Biogen Idec. as a consultant and/or speaker. Dr. Arnold...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Kappos, L., Selmaj, K., Arnold, D., Havrdova, E., Boyko, A., Kaufman, M., Wiendl, H., Rose, J., Greenberg, S., Sweetser, M., Riester, K., Elkins, J. Tags: Clinical Trial Outcomes in Multiple Sclerosis Source Type: research

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Conclusions: Our results suggest a beneficial effect of fingolimod on this marker of axonal injury and support the utility of NfL as a quantitative biomarker in multiple sclerosis.
Source: Neurology - April 20, 2015 Category: Neurology Authors: Kuhle, J., Disanto, G., Lorscheider, J., Stites, T., Chen, Y., Dahlke, F., Francis, G., Shrinivasan, A., Radue, E.-W., Giovannoni, G., Kappos, L. Tags: All Clinical trials, Cerebrospinal Fluid, Multiple sclerosis ARTICLE Source Type: research

Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients
Conclusions: These results do not have direct clinical implications but they may be useful for further understanding the mode of action of this immunotherapy for multiple sclerosis patients.
Source: Multiple Sclerosis - May 7, 2015 Category: Neurology Authors: Chiarini, M., Sottini, A., Bertoli, D., Serana, F., Caimi, L., Rasia, S., Capra, R., Imberti, L. Tags: Research Papers Source Type: research

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients
Conclusion: The safety, pharmacokinetic profile, and pharmacodynamic responses to GNbAC1 are favourable in MS patients over a six-month treatment period.
Source: Multiple Sclerosis - May 29, 2015 Category: Neurology Authors: Derfuss, T., Curtin, F., Guebelin, C., Bridel, C., Rasenack, M., Matthey, A., Du Pasquier, R., Schluep, M., Desmeules, J., Lang, A. B., Perron, H., Faucard, R., Porchet, H., Hartung, H.-P., Kappos, L., Lalive, P. H. Tags: Original Research Papers Source Type: research

Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue
Conclusion: Fatigue is associated with distinct alterations of basal ganglia functional connectivity independent of overall disability. The pattern of connectivity changes suggests that disruption of motor and non-motor basal ganglia functions, including motivation and reward processing, contributes to fatigue pathophysiology in multiple sclerosis.
Source: Multiple Sclerosis - May 29, 2015 Category: Neurology Authors: Finke, C., Schlichting, J., Papazoglou, S., Scheel, M., Freing, A., Soemmer, C., Pech, L., Pajkert, A., Pfuller, C., Wuerfel, J., Ploner, C., Paul, F., Brandt, A. Tags: Original Research Papers Source Type: research

School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis
Conclusion: Testing a premorbid cognitive deficit by a validated indirect evaluation method allowed us to verify that there was evidence of neurological compromise even before a clinical diagnosis or the completion of the first magnetic resonance imaging in patients who would then suffer from multiple sclerosis.
Source: Multiple Sclerosis - May 29, 2015 Category: Neurology Authors: Sinay, V., Perez Akly, M., Zanga, G., Ciardi, C., Racosta, J. M. Tags: Original Research Papers Source Type: research

Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis
Conclusion Treatment with peginterferon beta-1a could help to improve or maintain HRQoL in addition to clinical outcomes. Trial registration: ClinicalTrials.gov: NCT00906399.
Source: Multiple Sclerosis and Related Disorders - June 26, 2015 Category: Neurology Source Type: research